[1] 曹毛毛, 李贺, 孙殿钦, 等. 2000—2019年中国胃癌流行病学趋势分析[J]. 中华消化外科杂志, 2021, 20(1):102-109.
[2] ZAMORANO J L, LANCELLOTTI P, RODRIGUEZ MUNOZ D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37(36): 2768-2801.
[3] 刘光, 谢悦陶, 孙芳毅, 等. 老年肺癌患者应用贝伐珠单抗联合化疗发生急性心肌梗死救治体会一例[J]. 中华老年心脑血管病杂志, 2021, 23(8):872-874.
[4] PARK S H, LIM D H, SOHN T S, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial[J]. Ann Oncol, 2021, 32(3):368-374.
[5] 鲍予頔, 张辉, 董雷, 等. 局部进展期胃癌术后进行奥沙利铂联合替吉奥辅助化疗的安全性和有效性[J]. 中华胃肠外科杂志, 2021, 24(2):145-152.
[6] DEPETRIS I, MARINO D, BONZANO A, et al. Fluoropyrimidine-induced cardiotoxicity[J]. Crit Rev Oncol Hematol, 2018, 124:1-10.
[7] LI C, NGORSURACHES S, CHOU C, et al. Risk factors of fluoropyrimidine induced cardiotoxicity among cancer patients: a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2021, 162:103346.
[8] GUI Y, FAMUREWA A C, OLATUNJI O J. Naringin ameliorates 5-fluorouracil induced cardiotoxicity: an insight into its modulatory impact on oxidative stress, inflammatory and apoptotic parameters[J]. Tissue Cell, 2023, 81:102035.
[9] KAKEJI Y, YOSHIDA K, KODERA Y, et al. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage Ⅲ gastric cancer: JACCRO GC-07[J]. Gastric Cancer, 2022, 25(1):188-196.
[10] 任李, 张定国. 《2021ACC/AHA/SCAI冠状动脉血运重建指南》解读[J]. 实用心电学杂志, 2022, 31(4):229-237.
[11] 邰宵辉, 李红玲, 党春艳, 等. 抗肿瘤药物致心脏毒性41例临床分析[J]. 中国心血管病研究, 2022, 20(5):422-426. |
